Eniola's strongest angle is to position herself as the rare VSD applicant who arrives having already executed DSV's Year-1 and Year-2 cycles independently: three sole-authored CCT preprints constitute her scoping and hypothesis formation; ODE/RK45 + Bayesian MCMC validation (85.8% encoding-probability reduction, all five pre-registered hypotheses confirmed, super-additivity +12.8 pp) is her invention phase; and IMPRINT, TOPOLOGIX, and GATE are embryonic Year-3 ventures — she is already building the commercialisation layer. Endorsements from Berridge, Gershman, Daw, and Mattar map directly onto the high-calibre supervisor network the programme prizes, and her Nigerian/Lagos independent-researcher identity is the precise non-traditional, LMIC-origin, under-represented profile DSV states it explicitly wants to attract. The proposal should frame VSD not as a place to discover a problem, but as the institutional scaffolding (PhD credential via Woolf, lab network, 400+ investor access) that will allow an already-validated research arc to reach clinical and commercial scale within a Pharma-sector venture.

1. IP conflict risk: Eniola holds a provisional CCT patent (Q3 2026) and has pre-existing platforms (IMPRINT, TOPOLOGIX, GATE). The VSD model transfers IP developed during the programme to the new venture — terms for pre-existing IP are not publicly specified and must be clarified with DSV before application; if she continues CCT work inside VSD, ownership of derivative IP could become contested. 2. No Masters degree: With a B.Pharm as her highest qualification, standard PhD entry typically requires a Masters or research-honours degree. Woolf's specific minimum entry requirements for the VSD are not published on the website; the diversity mandate may mitigate this, but Eniola's planned MSc at MUG/Graz (Oct 2026 start) would not be complete before the April 2027 cohort begins — she should address this head-on in her application and confirm eligibility directly with DSV admissions. 3. Sector framing gap: DSV's Pharma portfolio clusters strongly around cancer (immunotherapy, gene therapy, biologics). Addiction pharmacology / computational neuroscience sits at the edge of this cluster; Eniola must explicitly reframe CCT within the 'curative therapeutics' and 'reward-circuit' language DSV uses, and link to the commercial size of the addiction treatment market, not just the science. 4. Small cohort = extreme competition: Cohort 3 was funded to only 5 slots by SPRIN-D. Even strong candidates face high rejection rates purely from supply constraints. 5. Relocation requirement: The programme involves physical presence at DSV London and a global lab network. Moving from Lagos to the UK/EU requires visa navigation, relocation costs, and financial planning — Eniola should demonstrate awareness of and a concrete plan for this in her personal statement. 6. UK-centric institutional network: Most partner institutions (Imperial, UCL, Edinburgh, NPL, James Hutton) are UK-based, which may reduce the EU/Africa research-network advantage Eniola might bring if she had MUG/Graz connections.